D. E. Shaw & Co. Inc. decreased its position in shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) by 74.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 56,200 shares of the biopharmaceutical company’s stock after selling 162,589 shares during the quarter. D. E. Shaw & Co. Inc.’s holdings in AVEO Pharmaceuticals were worth $38,000 as of its most recent SEC filing.
A number of other institutional investors have also recently added to or reduced their stakes in the stock. NEA Management Company LLC boosted its stake in AVEO Pharmaceuticals by 20.8% during the 2nd quarter. NEA Management Company LLC now owns 25,243,865 shares of the biopharmaceutical company’s stock worth $16,913,000 after acquiring an additional 4,347,827 shares during the last quarter. Vanguard Group Inc. boosted its stake in AVEO Pharmaceuticals by 26.7% during the 2nd quarter. Vanguard Group Inc. now owns 7,670,096 shares of the biopharmaceutical company’s stock worth $5,164,000 after acquiring an additional 1,614,802 shares during the last quarter. Paloma Partners Management Co bought a new position in AVEO Pharmaceuticals during the 2nd quarter worth approximately $321,000. Morgan Stanley boosted its stake in AVEO Pharmaceuticals by 265.4% during the 2nd quarter. Morgan Stanley now owns 399,742 shares of the biopharmaceutical company’s stock worth $269,000 after acquiring an additional 290,354 shares during the last quarter. Finally, Cetera Advisor Networks LLC bought a new position in AVEO Pharmaceuticals during the 2nd quarter worth approximately $38,000. 29.55% of the stock is currently owned by institutional investors and hedge funds.
AVEO traded down $0.01 during trading on Monday, reaching $0.82. The company had a trading volume of 3,005 shares, compared to its average volume of 1,973,756. The company has a debt-to-equity ratio of 6.84, a current ratio of 2.21 and a quick ratio of 2.21. AVEO Pharmaceuticals, Inc. has a 12 month low of $0.49 and a 12 month high of $2.85. The business’s fifty day moving average price is $0.82 and its 200 day moving average price is $0.79. The company has a market cap of $131.81 million, a P/E ratio of -4.32 and a beta of 0.71.
A number of research analysts have weighed in on the stock. Piper Jaffray Companies lifted their price target on shares of AVEO Pharmaceuticals from $3.00 to $4.00 and gave the company an “overweight” rating in a research note on Tuesday, September 10th. HC Wainwright reaffirmed a “buy” rating and issued a $1.75 price target on shares of AVEO Pharmaceuticals in a research note on Tuesday, October 1st. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company’s stock. AVEO Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $2.25.
AVEO Pharmaceuticals Profile
AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).
Further Reading: What are different types of coverage ratios?
Want to see what other hedge funds are holding AVEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO).
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.